Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma.

Maadi, Hamid; Soheilifar, Mohammad Hasan; Choi, Won-Shik; Moshtaghian, Abdolvahab; Wang, Zhixiang

Maadi, Hamid; Soheilifar, Mohammad Hasan; Choi, Won-Shik; Moshtaghian, Abdolvahab; Wang, Zhixiang.

Afiliação

Maadi H; Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada.
Soheilifar MH; Department of Medical Laser, Medical Laser Research Center, Yara Institute, ACECR, Tehran 1315795613, Iran.
Choi WS; Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada.
Moshtaghian A; Department of Molecular and Cell Biology, Faculty of Basic Sciences, University of Mazandaran, Babolsar 4741695447, Iran.
Wang Z; Deputy of Research and Technology, Semnan University of Medical Sciences, Semnan 3514799442, Iran.

Cancers (Basel) ; 13(14)2021 Jul 15.

Article em En | MEDLINE | ID: mdl-34298754

Palavras-chave

HER2; MAPK pathway; PI3K/AKT pathway; breast cancer; trastuzumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Canadá

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google